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Abstract
Isolation of Mycoplasma genitalium from clinical specimens remains difﬁcult. We describe a modiﬁed culture system based on Vero cells
grown in medium 199 with 2% foetal bovine serum (FBS). The culture system was evaluated using early passage M. genitalium strains M6271
and M6311 with growth monitoring by quantitative TaqMan PCR. Eleven endocervical swabs and one male urethral swab positive by 16S
rRNA and MgPa1–3 PCRs were quantiﬁed and inoculated into Vero cell suspensions in medium 199 supplemented with 2% FBS and
antibiotics. Cultures were incubated for 14 days. Cell passages and growth monitoring by TaqMan PCR were performed until the growth of
M. genitalium reached ≥106 geq/mL. Conﬁrmation of the new M. genitalium strains was performed by sequencing a 281 bp fragment of
mgpB. The growth of Mycoplasma genitalium strains was recorded for all urogenital swab specimens in the modiﬁed cell-culture system.
Growth of M. genitalium was obtained within 2 months and yielded 12 M. genitalium strains with all 11 isolates from females of an identical,
but unique genotype. To our knowledge, this is the ﬁrst successful isolation of M. genitalium in the Latin-American region. The use of Vero
cell culture in 199 medium with 2% FBS is a method comparable to the Ultroser G culture system for isolation of M. genitalium. Genotyping
of clinical samples and isolates should be performed to document the absence of cross-contamination.
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Introduction
Mycoplasma genitalium was ﬁrst isolated from urethral swabs
from patients with non-gonococcal urethritis in 1980 [1]. This
microorganism is now considered an established cause of male
non-gonococcal urethritis and female cervicitis [2, 3]. An
important improvement in the primary isolation procedure of
M. genitalium was the use of co-culture in Vero cells [4–6].
This methodology allows growth from clinical samples in
approximately 2 months, but is still extremely slow and labour
intensive [5, 6].
Vero and Hep-2 cells have been used for co-cultivation and
the best results were obtained using a serum-free medium [4].
Nevertheless, foetal bovine serum has shown good
growth-promoting capabilities for M. genitalium cell-assisted
growth and some strains were recovered from urine samples
using it [7]. At present, M. genitalium strains have been isolated
from samples in the Unites States of America, Europe, Japan
and Australia [1, 4–6], but no strains have been obtained from
the Latin-American region.
In Cuba, a previous study carried out by Rodrıguez et al. [8]
showed a high frequency of M. genitalium in men with
urethritis but, so far, no strains have been obtained from
Cuban patients, and genetic characteristics of the circulating
strains remain unknown. The isolation and genetic character-
ization of M. genitalium strains from Cuban patients is impor-
tant for studies of antimicrobial susceptibilities that permit a
better management of urogenital infection in men and women.
With the objective of isolating M. genitalium strains from
urogenital samples of Cuban patients, a modiﬁed co-culture
method was developed.
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Part of this work was presented at the 19th congress of the
International Organization for Mycoplasmology (IOM), Tou-
louse, France, 15–20 July 2012 (abstract no. 109).
Methods
All procedures below were performed in the National
Reference Laboratory for Mycoplasma Research at “Pedro
Kourı” Tropical Medicine Institute (IPK), Havana, Cuba. This
study was approved by the IPK Ethics Committee, and all
participants provided informed consent.
Cell culture and M. genitalium strains
Vero cells (ATCC CCL-81) were cultured in 199 medium
(Gibco, Paisley, Scotland, UK) with 5% foetal bovine serum
(FBS; Hyclone, Logan, UT, USA) for 7 days. M. genitalium
strains M6271 and M6311 only adapted to growth in cell
culture (obtained from the Mycoplasma Laboratory at Statens
Serum Institut, Denmark) were used as control strains for the
evaluation of the culture systems.
Real-time PCR for M. genitalium growth monitoring and
quantiﬁcation
LightCycler (Roche, Mannheim, Germany) TaqMan PCR
(qPCR) of a 78 bp fragment of the mgpB gene [9] was used.
Brieﬂy, an ‘in house’ PCR mix was prepared, containing per
PCR-reaction (20 lL): 19 of 109 PCR reaction buffer (25 mM
MgCl2; 2 mM deoxyribonucleotides, 2 mg/mL BSA, 100 mM
Tris HCl pH 8 and 500 mM KCl), 75 nM of MgPa-380 probe,
1 lM of MgPa-355F and MgPa-432R primers; and 1 U of
Taq-polymerase (Qiagen, Hilden, Germany). Five microlitres of
DNA extractions obtained by the osmotic and thermic shock
method [10] was used as template. In each run, 5 lL of
M. genitalium-DNA standards with concentrations of 1000, 100,
10 and 1 genome equivalent per lL (geq/lL) were used for
construction of the standard curve. The PCR set-up and analysis
were performed using a LightCycler 1.5 equipment (Roche). A
two-stepprogramdescribedby Jensenet al. in 2004 [9]wasused.
Cell culture system forM. genitalium isolation andpropagation
Vero cells in 199 medium with 2% of Hyclone–FBS, 19 of
vancomycin–colistin–nystatin–trimethoprim (VCNT) anti-
microbial supplement (Biolife, Milano, Italy) and 500 U/mL of
penicillin G (Sigma, St. Louis, MO, USA), was selected for
attempting the isolation of M. genitalium. The culture systems
was evaluated using an early passage of M. genitalium strains
M6271 and M6311, with growth monitoring by qPCR as
described above. Brieﬂy, cell culture supernatants of M6271
and M6311 strains were quantiﬁed and adjusted to contain
8 9 105 geq/mL. One millilitre of this standardized inoculum
was mixed with 3 mL of Vero-cell suspension (2.5 9 105 cells/
mL) in a cell-culture tube (Nunc, Roskilde, Denmark).
Cell-culture tubes were incubated at 37°C for 21 days. At
days 0, 7, 14 and 21; 0.1 mL of the cell culture supernatant was
harvested for monitoring the growth by qPCR.
Isolation of M. genitalium from clinical specimens
A modiﬁcation of the protocols described by Jensen et al. [4]
and Hamasuna et al. [5] was followed for the initial isolation of
M. genitalium from clinical specimens. Brieﬂy, a total of 12
M. genitalium PCR-positive urogenital specimens (11 endocer-
vical and one male-urethral swab) from 11 women and one
man with urogenital infections attending the “Pedro Kourı”
Tropical Medicine Institute’s Hospital, between February and
July of 2011 for sexually transmitted diseases, were used. The
samples were screened positive by a 16S rRNA PCR [11] for
M. genitalium and conﬁrmed as positive using the MgPa 1–3
PCR [12]. Quantiﬁcation of Mycoplasma genitalium was
performed by qPCR and aliquots of the M. genitalium-positive
specimens in Friis medium (FB medium) [4] were maintained at
80°C for attempts at isolation.
One millilitre of the frozen aliquot of positive sample was
thawed and diluted in 199 medium to obtain a ﬁnal
M. genitalium concentration of 2 9 104 geq/mL. Vero-culture
tubes containing 3 mL of Vero-cell suspension
(2.5 9 104 cells/mL) in 199 medium supplemented with 2%
FBS, 19 of VCNT and 500 U/mL of penicillin G, were
inoculated with 1 mL of the samples. The cells were observed
daily for the ﬁrst week and then at 2- to 3-day intervals. If
cells detached, fresh Vero cells were added (about
2.5 9 104 cells/mL). The medium was not changed during
the ﬁrst 14 days even if it was acidiﬁed.
Propagation of M. genitalium strains
Attached Vero cells were carefully scraped off 14 days after
the initial inoculation, and 2 mL of the cell-containing super-
natant was added to a new tube with 2 mL of a fresh Vero cell
suspension. At the same time, 0.1 mL was taken for growth
monitoring by qPCR. The remaining cell-containing medium
was stored at 80°C as back-up. When M. genitalium growth
was conﬁrmed by qPCR, and the concentration reached 106–
107 geq/mL, cell-containing medium was stored at 80°C for
future attempts of axenic isolation.
Sequencing of MgPa-1/MgPa-3 amplicons
Primary conﬁrmation of the new M. genitalium strains was
performed at the IPK by sequencing the 281 bp fragment of
the mgpB gene obtained by the conﬁrmatory PCR from
genomic DNA of early passage of the strains, using the
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methodology described by Hjorth et al. [13] PCR products
were puriﬁed using the QIAquick PCR Puriﬁcation kit (Qiagen)
and sequencing was performed using the Dye Terminator
Cycle Sequencing (DTCS) Quick Start Kit (Beckman Coulter,
Fullerton, CA, USA) the same primers as used for the
conﬁrmatory PCR. The sequencing fragments were resolved
on a genetic analysis system CEQ 8800 (Beckman Coulter).
Finally, the sequences were edited and assembled using
Sequencher, version 4.10 (Gene Codes Corporation, Ann
Arbor, MI, USA). The genotype was conﬁrmed at Statens
Serum Institute (SSI), Denmark, by sequencing the same
amplicon described above from the original clinical samples
and genomic DNA of early passage of the strains. Phylogenetic
analysis was conducted using MEGA software version 5.
Results
Evaluation of the cell culture system for M. genitalium
isolation and propagation
M. genitalium strains M6271 and M6311 successfully grew in
the selected culture system (Vero cells in 199 medium w/2%
FBS), showing a similar growth patterns as previously reported
for M. genitalium strains in cell culture [14]. The growth curve
of M. genitalium strains obtained by qPCR is shown in Fig. 1.
Growth of Mycoplasma genitalium was achieved 3 weeks
post-inoculation.
Isolation of M. genitalium from clinical specimens
The 12 M. genitalium-positive samples were quantiﬁed by
qPCR. All specimens showed M. genitalium concentrations
greater than 60 geq/lL (Table 1). Growth of the M. genitalium
strains was recorded from all 11 female urogenital swab
specimens and the single male urethral-swab specimen in the
modiﬁed cell-culture system. Growth in all positive samples
was obtained within a period of 2 months and yielded 12 new
M. genitalium isolates (Table 1). All the isolates had the
expected growth patterns as previously described by Hamas-
una et al. in 2005 [14].
Sequencing of MgPa-1/MgPa-3 amplicons
When the MgPa-typing method was applied on the isolates,
the same genotype was found in all the 11 female isolates
while the male isolate showed a different genotype (GenBank
accession nos. KF017612 and KF017613). All the strains were
different to G37T and to the other M. genitalium reference
strains that are maintained in our laboratory (Fig. 2). Sequenc-
ing results of the clinical samples showed that the male isolate
had the same genotype in clinical samples and in cell culture.
Unfortunately, none of the female clinical samples yielded any
amplicons when sequencing was attempted at SSI. The two
genotypes are new and have not been previously reported in
the literature.
Discussion
The use of Vero cells for isolation of M. genitalium has been
shown to be the best method for isolating new strains. The
original procedure was published by Jensen et al. [4] and
Hamasuna et al. [5], and described the use of a serum-free
medium: minimal essential medium supplemented with Ultroser
G serum substitute (Ciphergen, Cergy-Saint-Christophe,
France). However, in the present investigation, some modi-
ﬁcations were introduced and evaluated with early cell-culture
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FIG. 1. Growth curves of early passage of Mycoplasma genitalium
strains M6271 and M6311 in Vero cell culture in 199 medium with 2%
foetal bovine serum.
TABLE 1. Urogenital specimens cultured for Mycoplasma
genitalium
Sample
Specimen
type
Concentration
of M. genitalium
by qPCR
(geq/lL) Strain
First day of
conﬁrmed
M. genitalium
growth in Vero
cells
MICH 1 Endocervical 67 B1 70
RAPH 2 Endocervical 5.4 9 102 B2 42
GAB 3 Endocervical 6.7 9 102 B3 56
JOF 4 Endocervical 6.1 9 102 B4 28
CHAM 5 Endocervical 5.9 9 102 B5 28
URI 6 Endocervical 9.1 9 102 B6 28
ZAQ 7 Endocervical 7.5 9 102 B7 42
JC 8 Endocervical 1.6 9 102 B8 42
PHE 9 Endocervical 2.3 9 102 B9 42
JVH 10 Endocervical 1.5 9 102 B10 42
BAM 11 Endocervical 1.9 9 102 B11 14
347-U Urethral 5.8 9 104 B12 14
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passages of M. genitalium clinical strains. The modiﬁcation of
the culture system (cell media and supplements) showed that
199 medium with 2% FCS supports the growth similarly to
that reported for minimal essential medium with Ultroser
serum substitute [4]. Unfortunately, due to lack of availability
of Ultroser G, no direct comparisons could be performed.
The good results with the 199 medium make good sense as
the CMRL-1069 medium, which is used in the SP-4 culture
medium for fastidious mycoplasmas used to isolate M. geni-
talium for the ﬁrst time [1], is a modiﬁcation of the 199
medium. At present, only two reports on the use of
FBS-containing medium have been published, but none of
these used the 199 basal medium [4,7]. The use of a
low-serum concentration may permit enough growth-pro-
moting components of the serum but with less M. genitalium
growth-suppressing activity of antibodies and other com-
pounds in the serum. Although later results with 199 medium
with 10% of FBS has shown better grown-promoting prop-
erties for a few strains others have shown a slower grown
rate than in 199 medium with 2% FBS (data not shown).
Consequently, we recommend the use of 2% FBS as the
optimal concentration.
Due to the heavy bacterial contamination of female samples,
an additional antimicrobial supplement was needed. The
VCNT supplement was chosen because it is used routinely
in the selective media for Neisseria gonorrhoeae [15]. Addition-
ally, penicillin was included as this antibiotic has been shown
not to interfere with the growth of M. genitalium, although it
could be argued that the spectrum of this antibiotic was
covered already. The antibiotic mixture proved to be highly
efﬁcient as only the B1 isolate was contaminated with bacterial
over-growth at 7 days post-inoculation, but after a 0.45 lm
ﬁltration, the bacterial contamination was eliminated and the
M. genitalium strain was recovered.
The MgPa-1/3 genotyping clearly showed that all the
strains were different to G37T and the other M. genitalium
reference strains that are maintained in our laboratory
(Fig. 2). However, the high genetic homogeneity found in the
female isolates could probably only be explained by some
unfortunate cross-contamination between the cultures during
the prolonged handling of the cell cultures. Although the risk
of cross-contamination is well known, and although all
possible care was taken during the propagation of the cell
lines, it seems unlikely that the genotypes of all specimens
should be identical. Unfortunately, conﬁrmation of the
genotype directly from the clinical specimens failed for
technical reasons, so it is impossible to determine if more
than one of the female samples were of the same genotype
and leading to new, unique strains. However, the two
genotypes found in the male and female specimens were
unique when compared to previous entries in the public
databases, and thus, represent new strains. Future sequencing
studies will be performed to assess the genotype distribution
in the Cuban population.
To our knowledge, this is the ﬁrst successful isolation of
M. genitalium in the Latin-American region. Some previous
attempts using direct culture of clinical samples in SP-4 and
Friis media have been undertaken by our group but without
any successful results.
In conclusion, we successfully implemented a modiﬁcation
of the co-culture method allowing us to isolate M. genitalium
strains from at least two urogenital specimens from Cuban
patients. Although 12 specimens from PCR positive specimens
yielded cultivable strains we could only prove that two of them
represented genuine new strains stressing the need for
genotyping of both the clinical sample and the isolated strain.
Furthermore, the procedure is still slow and labour intensive
and other improvements in the culture methodology would be
advantageous. Future work will focus on adaptation of the
strains to growth in axenic culture and on determining the
antibiotic susceptibility proﬁle which is completely unknown in
Cuba at present. This will guide the optimal treatment of
M. genitalium infections in Cuba and possibly also in other
Latin-American countries.
FIG. 2. Dendrogram showing phylogenetic relationship between
Cuban isolates (B-strains: black circles identify the female isolates
and black triangles identify the male isolate) and Mycoplasma genitalium
reference strains (G37 and M-strains) maintained at “Pedro Kourı”
Tropical Medicine Institute (IPK).
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